Article · 19 Jun 2026
Conference abstract
Current evidence on the effect of DPP-4 inhibitordrugs on mortality in type 2 diabetic (T2D) patients: A meta-analysis
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
This meta-analysis throws light on the current understanding from concluded randomized controlled trials (RCTs) before 2014 on the extent of impact of dipeptidyl peptidase-4 inhibitor (DPP-4 I) drugs on overall mortality in patients of type 2 diabetes mellitus. TheDPP-4 inhibitor class representsa relatively newer class of oral antidiabetic agents that facilitate improved glycemic control and improvement in glycosylated haemoglobin levels (HbA1c) in patients with type 2 diabetes mellitus. The present meta-analysis is aimed at all randomized controlled trials involving that were published before February 2014 was carried out. Published articles in bibliographic and abstracting electronic databases such as Pubmed central, Cochrane reviews andother medical journals served as the data sources for the present study. The article selection criteria included all randomized placebo-controlled trials of at least one year duration and those which measured at least one of the following clinical endpoints: risk ratio, coronary artery disease mortality, cardio-vascular mortality or all-cause mortality. Information on sample size, follow up period, drug used, and clinical outcomes was abstracted independently by the authors. The present meta-analysis compiled pooled data from 18 randomised controlled trials (RCTs) fulfilling the inclusion criteria of the study (18 trials, 5903 patients) showed a significant relative risk reduction of coronary artery disease mortality, cardiovascular disease mortality and on all-cause mortality without any significant heterogeneity and inconsistency between the trials. From these findings was inferred from the findings from this meta-analyses that the dipeptidyl peptidase-4 inhibitors are indeed effective medicines that confer benefit to patients, in terms of affording optimal glycemic control in T2 DM patients and disease control.
Keywords
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Pharmacovigilance.
Article · 19 Jun 2026
Strengthening Healthcare Outcomes Through Effective Drug Safety Practices
Article · 19 Jun 2026
Expanding Patient Care Through Clinical Pharmacy Services in Modern Healthcare
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Pharmacovigilance
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Raja Chakraverty”
- BylineArticles whose byline prints “AmitavaGhosh”
